- Conditions
- Chronic Lung Disease, Hematopoietic Cell Transplantation, Graft Versus Host Disease
- Interventions
- Not listed
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 36 Months and older
- Enrollment
- 375 participants
- Timeline
- 2023 – 2028
- U.S. locations
- 6
- States / cities
- Stanford, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 7,387
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Malaria, Vivax
- Interventions
- Tafenoquine, Dihydroartemisinin + Piperaquine tetraphosphate, Artemether + Lumefantrine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy
- Interventions
- Esketamine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
- Interventions
- CBX-12
- Drug
- Lead sponsor
- Cybrexa Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Austin, Texas • Houston, Texas + 1 more
- Conditions
- Type 2 Diabetes
- Interventions
- exenatide once weekly, basal insulin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- Not listed
- Enrollment
- 6,024 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndromes
- Interventions
- Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine
- Drug
- Lead sponsor
- Mateon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Gainesville, Florida • Miami, Florida + 1 more
- Conditions
- Previously Treated CD20+ B-cell Malignancies
- Interventions
- ocaratuzumab
- Biological
- Lead sponsor
- Mentrik Biotech, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2015
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism
- Interventions
- CTAP101, Placebo
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Greenville, South Carolina
- Conditions
- Opioid-use Disorder
- Interventions
- Blood sample collection, Urine sample collection
- Diagnostic Test
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 11
- States / cities
- Hamilton, Alabama • Tampa, Florida • Prairie Village, Kansas + 7 more
- Conditions
- Ovarian Neoplasms
- Interventions
- Niraparib, Carboplatin, Paclitaxel
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 11
- States / cities
- San Francisco, California • Miami, Florida • Tampa, Florida + 7 more
- Conditions
- Ulcerative Colitis
- Interventions
- Mirikizumab SC, Mirikizumab IV, Placebo SC
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 57
- States / cities
- Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 51 more
- Conditions
- Persistent Pulmonary Hypertension of the Newborn
- Interventions
- 1 dose of sildenafil
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Up to 364 Days
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • Louisville, Kentucky + 6 more
- Conditions
- Multiple Myeloma
- Interventions
- Etentamig, Lenalidomide, Daratumumab, Dexamethasone
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2042
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 12 more
- Conditions
- Choroidal Melanoma
- Interventions
- Ranibizumab 2 mg, 0.5 mg Ranibizumab
- Drug
- Lead sponsor
- New England Retina Associates
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Hamden, Connecticut
- Conditions
- Peritoneal Diseases
- Interventions
- Pre-ERAS® phase (current clinical practice), Post-ERAS® implementation phase
- Other
- Lead sponsor
- Hospices Civils de Lyon
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 288 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bortezomib, vorinostat
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Superficial Basal Cell Carcinoma
- Interventions
- PEP005
- Drug
- Lead sponsor
- Peplin
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 9
- States / cities
- Mesa, Arizona • Oceanside, California • San Diego, California + 6 more
- Conditions
- Lung Cancer
- Interventions
- bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, 3-dimensional conformal radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 3
- States / cities
- Chapel Hill, North Carolina • Concord, North Carolina • Winston-Salem, North Carolina
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Trastuzumab deruxtecan
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 9
- States / cities
- La Jolla, California • Aurora, Colorado • Tampa, Florida + 6 more
- Conditions
- Multiple Myeloma
- Interventions
- Medication Event Monitoring System
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Malignant Brain Neoplasm, Malignant Glioma
- Interventions
- Near-Infrared Fluorescence Imaging, Panitumumab, Panitumumab-IRDye800, POINPOINT-IR9000
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma, Gastroesophageal Cancer (GC), Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastroesophageal Junction (GEJ) Cancer, Gastrointestinal Cancer Metastatic, Gastrointestinal Adenocarcinoma, Gastrointestinal Cancers, Colorectal (Colon or Rectal) Cancer, Pancreatic Cancer, CDH17-positive Advanced Solid Tumors, Advanced Gastric Cancer
- Interventions
- BHB810
- Drug
- Lead sponsor
- BigHat Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Duarte, California • Santa Monica, California • Fairfax, Virginia
- Conditions
- Schizophrenia
- Interventions
- RBP-7000, risperidone
- Drug
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Willingboro, New Jersey
- Conditions
- Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
- Interventions
- KIN-2787, KIN-2787 and binimetinib
- Drug
- Lead sponsor
- Pierre Fabre Medicament
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 15
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 11 more